Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

American Virtual Cloud Tech Inc (AVCT)

American Virtual Cloud Tech Inc (AVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the US under its Investigational...

AVCT.LN : 73.000 (-1.22%)
AVCT : 0.5980 (-11.01%)
Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces the opening on 5 April 2023 of the first two clinical investigator...

AVCT : 0.5980 (-11.01%)
Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the...

AVCT.LN : 73.000 (-1.22%)
AVCT : 0.5980 (-11.01%)
Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announced the appointment of Karen Harrison as Chief Operating Officer...

AVCT.LN : 73.000 (-1.22%)
AVCT : 0.5980 (-11.01%)
Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics announces that AVA6000 continues to show a very favourable safety profile in...

AVCT : 0.5980 (-11.01%)
Don’t Chase American Virtual Cloud Technologies Higher

American Virtual Cloud Technologies rocketed higher to start the month but don't go chasing prices until you know the whole story.

AVCT : 0.5980 (-11.01%)
T : 19.12 (-0.16%)
IBM : 183.25 (-1.06%)
CRM : 247.63 (+0.11%)
ZM : 58.87 (-0.47%)
Pre-Market Brief: Stocks Mixed as Economic Outlook Darkens

December S&P 500 futures (ESZ22) are trending up +1.03% after three major US benchmark indices continued to fall deeper into correction territory during the regular trading session as investors fretted...

ESZ22 : 3,871.47s (-0.66%)
AMLX : 2.02 (+1.00%)
MSFT : 437.11 (-0.74%)
NKE : 72.70 (+0.44%)
PATH : 12.05 (-0.33%)
AVCT : 0.5980 (-11.01%)
Avacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug Administration

Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer ® and pre|CISION™ platforms, announces that the US Food and...

AVCT.LN : 73.000 (-1.22%)
AVCT : 0.5980 (-11.01%)
Avacta Announces Phase I Clinical Study of AVA6000 to Advance to the Fourth Cohort

Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer ® and pre|CISION™ platforms, announces that the first-in-human...

AVCT : 0.5980 (-11.01%)
LG Chem Renews License Triggering Payment to Avacta

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer ® and pre|CISION™ platforms,...

AVCT.LN : 73.000 (-1.22%)
AVCT : 0.5980 (-11.01%)

Barchart Exclusives

3 Highest-yielding Dividend Aristocrats With Strong-buy Ratings
Discover the top three highest-rated, highest-yielding Dividend Aristocrats for your retirement portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar